Mid-Day Market Update: Crude Oil Down 2.5%; Exicure Shares Spike Higher
Midway through trading Monday, the Dow traded up 0.35% to 35,058.26 while the NASDAQ rose 0.52% to 14,748.83. The S&P also rose, gaining 0.39% to 4,412.29.
40 Stocks Moving In Monday’s Mid-Day Session
Gainers
Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program.
TG Therapeutics Q2 EPS $(0.59) Misses $(0.50) Estimate, Sales $1.54M Up From $38.00K YoY
TG Therapeutics (NASDAQ:TGTX) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.50) by 18 percent. This is a 25.53 percent decrease over losses of $(0.47) per share from
Earnings Scheduled For August 2, 2021
Companies Reporting Before The Bell
• HSBC Holdings (NYSE:HSBC) is estimated to report earnings for its second quarter.
TG Therapeutics Wins $20M Contract From Department Of Veterans Affairs For ‘Drugs, Pharmaceuticals, and Hematology Products’
https://sam.gov/opp/bcf5016a80cf4a6faead8dded139dcb1/view
Looking Into TG Therapeutics’s Return On Capital Employed
During Q1, TG Therapeutics's (NASDAQ:TGTX) reported sales totaled $793.00 thousand. Despite a 2.07% in earnings, the company posted a loss of $88.73 million. In Q4, TG Therapeutics brought in $38.00 thousand in sales but lost $86.93 million in earnings.
TG Therapeutics Highlights Presentation Of TG-1701 Data At International Congress On Malignant Lymphoma
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced data from two presentations evaluating TG-1701, the Company's investigational once-daily, oral BTK inhibitor, presented today during the 16th International
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
Recap: TG Therapeutics Q1 Earnings
Shares of TG Therapeutics (NASDAQ:TGTX) remained unaffected after the company reported Q1 results.
Quarterly Results
Earnings per share were down 43.75% year over year to ($0.69), which missed the estimate of ($0.49).